

**Table S2.** Mean DTF-QoL single item scores ( $\pm$ SD) in relation to socio-demographic and clinical characteristics

		DTF-QoL single items <sup>+</sup>					
		Decreased libido	Hair loss	DTF changed life in negative way	Hair colour change	Wasting time of cancer specialists	Rash treatment
Age (years)							
	18-39	23.1 (31.4)	11.7 (25.6)	39.3 (34.4)	6.3 (19.8)	14.2 (26.0)	14.0 (28.4)
	≥40	28.1 (36.3)	10.2 (23.3)	27.7 (31.2)	7.4 (18.8)	9.0 (19.3)	10.1 (25.0)
	<i>P</i> -value	0.442	0.703	<b>0.007</b>	0.364	0.136	0.174
Sex							
	Male	16.4 (29.6)	5.4 (18.3)	30.6 (31.5)	8.8 (24.8)	4.3 (11.3)	12.9 (26.6)
	Female	28.9 (34.7)	12.9 (26.1)	34.5 (33.9)	6.1 (16.8)	14.3 (25.5)	11.7 (26.9)
	<i>P</i> -value	<b>0.011</b>	<b>0.016</b>	0.499	0.857	<b>0.006</b>	0.527
Relationship status							
	Partnered	25.9 (33.9)	11.4 (25.1)	32.2 (32.0)	7.0 (19.4)	11.0 (21.7)	10.6 (25.6)
	Not partnered	23.8 (33.9)	8.8 (21.8)	37.7 (37.6)	6.4 (19.2)	13.8 (27.3)	16.4 (30.4)
	<i>P</i> -value	0.714	0.512	0.469	0.815	0.730	0.122
Education level							
	Low	24.0 (35.4)	4.6 (14.1)	25.9 (28.9)	6.7 (22.1)	12.0 (22.8)	6.5 (15.6)
	Medium	26.8 (32.8)	12.4 (26.6)	36.5 (35.4)	7.1 (19.7)	8.5 (18.8)	12.1 (27.3)
	High	23.8 (35.0)	11.4 (24.4)	32.0 (31.1)	6.3 (17.4)	16.9 (28.4)	14.6 (29.9)
	<i>P</i> -value <sup>#</sup>	0.826	0.236	0.218	0.958	<b>0.044<sup>a</sup></b>	0.330
Employment status							
	Working	23.1 (31.4)	8.6 (21.1)	31.8 (31.2)	4.8 (16.1)	12.7 (24.1)	11.7 (26.8)
	Not working	30.7 (38.5)	15.4 (29.5)	36.7 (37.0)	11.5 (24.6)	9.6 (20.7)	12.7 (26.8)
	<i>P</i> -value	0.299	0.133	0.516	<b>0.021</b>	0.328	0.662
Comorbidity							
	None	16.5 (30.1)	7.4 (22.2)	31.1 (31.9)	5.1 (17.5)	12.6 (23.7)	12.2 (26.7)
	1	25.8 (35.0)	12.6 (25.1)	32.0 (33.8)	4.6 (16.5)	8.6 (19.2)	6.9 (21.6)
	≥2	37.9 (33.9)	13.6 (26.2)	38.0 (34.4)	11.5 (23.5)	13.6 (25.6)	16.9 (30.8)
	<i>P</i> -value <sup>#</sup>	<b>0.001<sup>b</sup></b>	0.215	0.382	0.078	0.368	0.084
Time since diagnosis							
	<5 years	25.9 (34.4)	10.3 (25.6)	32.8 (32.8)	4.4 (14.4)	11.1 (21.8)	8.9 (24.6)
	≥5 years	24.9 (33.2)	11.6 (23.0)	34.3 (33.9)	9.5 (23.4)	12.3 (24.5)	15.7 (28.8)
	<i>P</i> -value	0.928	0.229	0.787	0.068	0.875	<b>0.008</b>
Treatments received <sup>1</sup>							
	Only surveillance	21.6 (30.0)	6.9 (19.8)	21.8 (26.3)	2.6 (10.5)	9.6 (19.6)	0.8 (5.1)
	Only surgery	18.6 (29.9)	5.2 (14.8)	25.5 (30.1)	5.6 (16.8)	12.0 (24.0)	6.9 (19.1)
	Other	35.2 (38.6)	19.4 (31.6)	51.6 (34.5)	11.7 (25.5)	13.5 (25.4)	27.4 (36.3)
	<i>P</i> -value <sup>#</sup>	<b>0.009<sup>c,d</sup></b>	<b>&lt;0.001<sup>c,d</sup></b>	<b>&lt;0.001<sup>c,d</sup></b>	<b>0.011<sup>c</sup></b>	0.535	<b>&lt;0.001<sup>c,d</sup></b>
Recurrent disease							
	Yes	23.1 (30.7)	8.1 (19.4)	46.3 (32.3)	7.9 (25.0)	13.0 (26.7)	23.6 (36.7)
	No	26.0 (34.5)	11.5 (25.4)	30.8 (32.9)	6.6 (17.8)	11.3 (22.2)	9.5 (23.5)
	<i>P</i> -value	0.734	0.529	<b>0.003</b>	0.618	0.991	<b>0.005</b>
Recurrent disease after surgery (n=98)							
	Yes	23.1 (30.7)	8.1 (19.4)	46.3 (32.4)	7.9 (25.0)	13.0 (26.7)	23.6 (36.7)
	No	20.9 (32.6)	8.8 (23.2)	26.3 (33.2)	6.1 (17.6)	10.5 (22.9)	8.3 (23.1)
	<i>P</i> -value	0.625	0.897	<b>0.002</b>	0.689	0.685	<b>0.010</b>
Tumour location							
	Abdominal wall	24.7 (35.0)	8.6 (20.3)	27.0 (34.5)	3.3 (10.1)	12.6 (22.4)	4.2 (14.3)
	Intra-abdominal	17.2 (32.9)	14.5 (32.3)	29.9 (32.3)	10.8 (22.8)	5.1 (14.4)	11.1 (24.6)
	Upper extremity	33.3 (39.5)	4.6 (14.7)	34.5 (28.8)	14.3 (30.7)	12.6 (16.5)	20.7 (36.1)
	Lower extremity	20.0 (27.4)	10.6 (21.5)	48.5 (35.2)	13.3 (27.4)	10.6 (21.5)	25.8 (35.5)
	Head/neck	26.7 (37.8)	38.5 (42.7)	38.5 (42.7)	5.6 (13.0)	5.1 (12.5)	7.7 (20.0)
	Trunk	27.1 (32.0)	7.4 (16.7)	30.2 (29.2)	1.4 (9.5)	15.4 (30.2)	11.1 (27.5)
	Hip/pelvis/gluteal region	29.6 (32.1)	11.7 (24.8)	46.7 (34.9)	5.6 (17.1)	15.0 (29.6)	13.3 (27.4)
	<i>P</i> -value <sup>#</sup>	0.656	<b>0.001<sup>e,f,g,h,i,j</sup></b>	0.083	<b>0.032<sup>*</sup></b>	0.396	<b>0.026<sup>k</sup></b>

<sup>+</sup> Higher scores indicate a higher level of symptomatology / problems.

<sup>1</sup> Active surveillance only and surgery only: including patients who received analgesics; Other treatment including patients who received only systemic therapy (i.e. chemotherapy, hormonal therapy, targeted medical therapy) or targeted therapy (i.e. radiotherapy, isolated limb perfusion, high-intensity focused ultrasound, cryoablation) or a combination of any form of active treatments.

Bold values indicate significant variables ( $P < 0.05$ )

#  $P$ -value of ANOVA for differences between the subgroups

\* No statistically significant differences in Bonferroni post hoc analysis

a, b, c, d, e, f, g, h, i, j, k Shows which groups are significantly different according to the Bonferroni post hoc analysis ( $P < 0.05$ ):

- Medium education level versus: <sup>a</sup> high
- $\geq 2$  comorbidities versus: <sup>b</sup> none
- Other treatment versus: <sup>c</sup> surveillance only, <sup>d</sup> surgery only
- Head and neck versus: <sup>e</sup> abdominal wall, <sup>f</sup> intra-abdominal, <sup>g</sup> upper extremity, <sup>h</sup> lower extremity, <sup>i</sup> trunk, <sup>j</sup> hip/pelvis/gluteal region
- Abdominal wall versus: <sup>k</sup> lower extremity